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Abstract:  
Objectives  
The aim of this study was to characterize OXA-258 variants and other features that may 
contribute to the carbapenem resistant in Achromobacter ruhlandii.  
Methods 
Kinetic parameters for purified OXA-258a and OXA-258b were determined measuring the 
rate of hydrolysis of a representative group of antibiotics. Whole-genome shotgun 
sequencing was performed on A. ruhlandii 38 (producing OXA-258a) and A. ruhlandii 319 
(producing OXA-258b) and in silico analysis of antimicrobial resistant determinants was 
conducted. Substrates of AxyABM efflux pump were investigated by inhibition assays 
using phenylalanine (Phe)-arginine (Arg)-β-naphthylamide. Outer membrane proteins 
profiles were resolved by 12% SDS-PAGE.  
Results 
Kinetic measurements of purified OXA-258 variants displayed an overall weak catalytic 
efficiency toward β-lactams. A detectable hydrolysis of imipenem was observed.  
In silico genomic analysis confirmed the presence of 32 and 35 putative efflux pump 
coding genes in A. ruhlandii 38 and 319, respectively. Complete sequences for AxyABM 
and AxyXY efflux pumps, previously described in Achromobacter xylosoxidans, were 
detected. Decrease in the MIC values for chloramphenicol, nalidixic acid, trimethoprim-
sulfamethoxazole was observed in the presence of inhibitor suggesting that these 
antibiotics are substrates of AxyABM. AxyXY coding genes of A. ruhlandii 38 and A. 
ruhlandii 319 displayed 99% identity between them. No differences were observed in the 
outer membrane proteins profiles.  
Conclusions 
The contribution of OXA-258a enzymes to the final β-lactam resistance profile may be 
secondary. Further studies on other putative resistance markers identified in the whole 
genome analysis should be conducted to understand the carbapenem resistance observed 
in A. ruhlandii. 
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1. Introduction 
Achromobacter spp. are non-frequent nosocomial and community pathogens able to 
cause infections in patients with underlying diseases and immunocompromised (1, 2). 
Although A. xylosoxidans is the most frequent species recovered within this genus, other 
species have been also associated with human infections (3, 4). A. ruhlandii is considered 
an opportunistic pathogen known to be resistant to a wide range of antibiotics, however, 
the knowledge about the resistance mechanisms is limited. In a previous study we 
described two allelic variants of a new class D β-lactamase named OXA-258, which 
constitutes a naturally occurring β-lactamase in A. ruhlandii (5). OXA-258a differs from 
OXA-114a of A. xylosoxidans by 40 amino acids, displaying 85% identity (6). OXA-258a was 
detected in a carbapenem resistant strain, while OXA-258b was identified in a 
carbapenem susceptible one. This latter differs from OXA-258a in one amino acid, R170H, 
according to the class D β-lactamase numbering scheme (7). The aim of this study was to 
characterize these OXA-258 variants and other features that may contribute to the 
carbapenem resistant profile observed in A. ruhlandii. 
2. Methods 
2.1 Bacterial isolates 
Carbapenem resistant A. ruhlandii 38, producing the allelic variant OXA-258a, and 
carbapenem susceptible A. ruhlandii 319, producing OXA-258b, were included (5).  
As indicated below, different recipient strains were used for cloning and expression 
assays. 
2.2 β-Lactamase production and purification 
Full length blaOXA-258 variants were amplified by PCR using custom designed primers 
OXA-258F (5’ AGCCATATGGACGTCCTGTGCACCCT 3’), containing the NdeI restriction site, 
and OXA-258R (5’ TGCTCGAGTTTGCGGGGCGCCGCGACCAT 3’), containing the XhoI 
restriction site. The NdeI-XhoI fragments of blaOXA-258a and blaOXA-258b were cloned into the 
pK19 vector and into the pET-28a(+) expression vector (Novagen, Inc., Madison, WI). The 
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authenticity of the cloned fragments was confirmed by sequencing. Escherichia coli TOP 
10F’ (F'[lacIq Tn10(tetR)] mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 deoR nupG 
recA1 araD139 Δ(ara-leu)7697 galU galK rpsL(StrR) endA1 λ-) was transformed with the 
pK19-OXA-258a and pK19-OXA-258b recombinant plasmids, and the MICs of a 
representative panel of β-lactam antibiotics were determined using the broth 
microdilution test according to the CLSI (8). 
pET-OXA-258a and pET-OXA-258b recombinant plasmids were introduced into E. coli 
BL21(DE3) (Novagen) to overproduce OXA-258a and OXA-258b, respectively. Overnight 
cultures of E. coli BL21(DE3)-pET-OXA-258a and E. coli BL21(DE3)-pET-OXA-258b were 
diluted (1/20) in 1 liter of LB medium containing 30 µg/ml of kanamycin and grown at 37°C 
until 0.8 OD units ( = 600 nm). IPTG was added at a final concentration of 1mM and 
cultures were grown at 18°C overnight. After centrifugation at 8,000 g at 4ºC, cells were 
suspended in 25 ml of 25 mM phosphate buffer (pH 7.5) and disrupted by sonication. 
Cellular debris were separated by centrifugation. The supernatant fractions displayed the 
highest specific activities when measured spectrophotometrically using 100 μM 
cephalothin as substrate. Each supernatant fraction was clarified by centrifugation at 
18.000 g for 30 min and filtering through a 0.22 μm pore filter membrane. The samples 
were loaded onto a 5ml HisTrap FF affinity column (flow rate, 0.5 ml/min) (GE Healthcare 
Life Sciences, USA) equilibrated with binding buffer (25 mM phosphate buffer +10 mM 
imidazole, pH 7.5). The column was extensively washed to remove unbound proteins. β-
lactamases were eluted with a step gradient of 25 mM phosphate buffer supplemented 
with imidazole 100, 200 and 300 mM, pH 7.5. β-lactamase containing fractions were 
pooled and dialyzed overnight against 25 mM phosphate buffer (pH 7.5) containing 50 
mM NaHCO3. Purified OXA-258a and OXA-258b were stored at -20°C until use. Enzymes 
purity was over 99% as estimated by SDS-PAGE. The HisTag could not be removed as 
thrombin cleavage sites are present within the sequence of both enzymes. 
2.3 Kinetic studies 
Kinetic parameters (kcat and Km) were determined measuring the rate of hydrolysis of 
different substrates using a UV/Vis spectrophotometer. The reactions were performed at 
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25°C in 25 mM phosphate buffer (pH 7.5) containing 50 mM NaHCO3 in order to avoid 
biphasic kinetics (6, 9). The kcat and Km values were determined for a representative set of 
β-lactam antibiotics: oxacillin, cephalothin, cephalexin, cephazolin, ceftazidime, 
cefotaxime, cefepime and imipenem. 
2.4 In silico analysis of antimicrobial resistant determinants  
Whole-genome shotgun sequencing was performed in OXA-258a and OXA-258b A. 
ruhlandii producing strains (A. ruhlandii 38 and A. ruhlandii 319, respectively) with 
Illumina MiSeq-I, using Nextera XT libraries for sample preparation. De novo assembly was 
performed with the SPAdes assembler version 3.1.0 (10), using a preassembly approach 
with Velvet (11). RAST server was used to predict all open reading frames and search for 
the blaOXA-258a and blaOXA-258b and their genetic context (12). BLAST (version 2.0) software 
was used to confirm the predictions. The presence of other resistance determinants was 
assessed by ARDB (13) and InterProScan (EMBL-EBI), and the existence of insertion 
sequences (IS), inverted repeat sequences (IR) or strong promoters were performed using 
ISfinder (14) and b-prom (Softberry) programs. 
2.5 Phenotypic characterization of efflux pump AxyABM in A. ruhlandii  
Inhibition assays were conducted in order to evaluate the contribution of the efflux 
pump AxyABM, previously described in A. xylosoxydans (15), in the imipenem resistance 
profile. Efflux pump coding genes were cloned into pK19 and transformed in E. coli TOP 
10F’. Minimal inhibitory concentrations of chloramphenicol (CHL), nalidixic acid (NAL), 
trimethoprim-sulfamethoxazole (SXT), ceftazidime (CAZ), imipenem (IPM), ciprofloxacin 
(CIP) and norfloxacin (NOR) were determined in the presence and absence of 25 µg/ml of 
the inhibitor phenylalanine (Phe)-arginine (Arg)-β-naphthylamide (PAβN), in A. ruhlandii 
38 and in the transformant E. coli TOP 10F’ + pK19-AxyABM (16). A reduction of ≥ 2 
dilutions in the MICs values of the antibiotic combined with PAβN respect the MIC of the 
antibiotic, was considered as positive inhibition (17).  
2.6 Analysis of outer membrane porins 
Porins extraction was performed according to Hancock and Poxton method and were 
resolved by 12% SDS-PAGE (18).  
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OprD homolog genes were investigated by whole-genome sequencing using RASTk 
server, and pfam and genbank databases. 
3. Results 
No differences were observed in the imipenem MIC values between transformants 
carrying OXA-258a and OXA-258b coding genes (Table 1a). β-lactam hydrolytic parameters 
are shown in Table 1b. Similar values were observed for both enzymes, displaying an 
overall weak catalytic efficiency toward the β-lactams included. No hydrolysis was 
detected for oxacillin and expanded-spectrum cephalosporins, neither for OXA-258a nor 
OXA-258b, as previously observed for other “oxacillinases”, such as the naturally occurring 
OXA-114a from A. xylosoxidans (6). A detectable hydrolysis of imipenem was observed, 
however kcat values could not be obtained because of high Km values, indicating a very 
poor affinity for this substrate.  
In silico genomic analysis confirmed the presence of 3 putative β-lactamase coding 
genes in each isolate. One of these open reading frames corresponded to blaOXA-258  allelic 
variants (blaOXA-258a  in A. ruhlandii 38 and blaOXA-258b in A. ruhlandii 319). Both markers had 
the same genetic context in the closest surrounding regions, however some differences 
could be observed in downstream remote regions. No insertion sequences (IS), inverted 
repeat sequences (IR) or strong promoters were identified upstream blaOXA-258 alleles 
(Figure 1). About the other 2 β-lactamase putative genes they codified for molecular class 
A and class C enzymes β-lactamases, which will be subject of further studies.  
Thirty two putative efflux pump coding genes were found in A. ruhlandii 38 genome, 
while 35 in A. ruhlandii 319 (GenBank accession nos. PHIH00000000 and PHIK00000000). 
Among them, complete sequences for two RND efflux pumps, previously characterized in 
A. xylosoxidans (15, 19) were detected in both genomes. One of them presented 98% 
identity with AxyABM of A. xylosoxidans and presented 99% identity between isolate 38 
and 319. MIC values for PaβN inhibition assays are shown in Table 2. A decrease in the 
MIC values for CHL, NAL and SXT was observed in the presence of PaβN in the 
transformant TOP 10-pK19–AxyABM, suggesting that these antibiotics are substrates of 
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AxyABM efflux pump. No changes were observed in the MIC values of CAZ, IPM, CIP and 
NOR in the presence of the inhibitor.  
The complete sequence for AxyXY-OprZ coding genes displays 99% identity with the 
previously described in A. xylosoxidans (19). It has been reported that carbapenems, 
fluoroquinolones and aminoglycosides are substrate of this efflux pump. Using the BLAST 
program, axyZ, axyX, and axyY genes could be detected in A. ruhlandii 38 and 319 
genomes, sharing 99% nucleotide similarity with the corresponding genes in A. 
xylosoxidans. Downstream axyY, it was located oprZ which encodes for an outer 
membrane protein that differs from OprZ of A. xylosoxidans by 2 amino acid, displaying 
99% identity. No major differences were observed in AxyXY coding genes between A. 
ruhlandii 38 and A. ruhlandii 319. 
No differences in the outer membrane proteins banding profile were observed among 
these isolates (data not shown). However, in silico genomic analysis showed the presence 
of 13 putative outer membrane coding genes in A. ruhlandii 38, while in A. ruhlandii 319 
there were detected 15. No Pseudomonas aeruginosa OprD porin homologues were found 
in A. ruhlandii. 
 
4. Discussion 
Here we describe the kinetic parameters for both allelic variants of the A. ruhlandii 
naturally occurring class D OXA-258. Despite the different resistance profiles observed in 
A. ruhlandii clinical isolates, no significant differences were observed between OXA-258a 
and OXA-258b respect β-lactam hydrolysis. It has been hypothesized for the naturally 
occurring OXA-114 in A. xylosoxidans that its expression could be influenced by the 
presence of IS, leading to a higher level of OXA-114-mediated β-lactam resistance (6). 
However, in the analysis of blaOXA-258 environment up to 5 Kb upstream blaOXA-258, not a 
single genetic element able to contribute to an increased expression level of the enzymes 
or recombination sites, was detected. It is likely that the contribution of OXA-258 enzymes 
to the final β-lactam resistance profile may be secondary, as previously demonstrated for 
the naturally occurring oxacillinase of A. xylosoxidans. 
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Here we also describe in A. ruhlandii the presence of two efflux pumps homologous to 
those previously reported in A. xylosoxidans. Accordingly, AxyABM in A. ruhlandii is able to 
extrude CHL and SXT but not imipenem. As suggested by Bador et al. AxyXY-oprZ in A. 
xylosoxidans, may be involved in acquired resistance to carbapenem and fluoroquinolone, 
which are antibiotics widely used to treat pulmonary infections in cystic fibrosis patients. 
However its presence was observed in both susceptible and resistant A. ruhlandii isolates.  
Further studies on other putative resistance markers identified in the whole genome 
analysis should be conducted to understand the carbapenem resistance observed in A. 
ruhlandii as the multiple approaches evaluated in this study are still not conclusive. 
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Figure 1: Genetic context of blaOXA-258 genes. Arrows represent the direction of transcription. The grey box indicates the region coding for the same 
protein.  
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Table 1: a) β-lactams MICs for A. ruhlandii strains (38 and 319), E. coli TOP10F’ harboring pK19 plasmid, E. coli TOP10F’ harboring pK19 plasmid expressing 
OXA-258a and OXA-258b, and E. coli TOP10F’ (reference strain). b) Kinetic parameters of purified β-lactamase OXA-258a and OXA-258b. 
    b)  
   
a) 
 
 
 
 
 
 
 
CEF: cephalothin; CFZ: cefazolin; LEX: cephalexin, FOX: cefoxitin; CAZ: ceftazidime;  
FEP: cefepime; IPM: imipenem 
 
  
 
 
ND: No detectable hydrolysis 
 
 
Antibiotic Enzyme Km (μM) kcat (s-1) kcat/Km(mM−1 .s−1) 
Oxacillin  
OXA-258a 
ND 
OXA-258b 
Cephalothin  
OXA-258a 
Biphasic Biphasic - 
OXA-258b 
Cephalexin  
OXA-258a 425 ± 55 0.034 ± 0.003  0.08± 0.02 
OXA-258b 352 ± 69 0.023 ± 0.002  0.06 ± 0.02 
Cephazolin  
OXA-258a 49 ± 4  0.0099 ± 0.0003 0.20 ± 0.02 
OXA-258b 33 ± 3 0.0080 ± 0.0002 0.24 ± 0.03 
Ceftazidime  
OXA-258a 
ND 
OXA-258b 
Cefotaxime  
OXA-258a 
ND 
OXA-258b 
Cefepime  
OXA-258a 
ND 
OXA-258b 
Imipenem  
OXA-258a 
Detectable hydrolysis. Poor affinity for this substrate. 
OXA-258b 
Nitrocefin  
OXA-258a 6.6 ± 0.9 0.51 ± 0.02 80 ± 20  
OXA-258b 7.4 ± 0.6 0.77 ± 0.02  104 ± 11 
  MIC (μg/ml) 
 
CEF CFZ LEX FOX CAZ FEP IPM 
E. coli TOP 10F’ 4 2 8 2 0.25 ≤ 0.125 0.25 
E. coli TOP 10F’ + pK19  4 2 8 2 0.25 ≤ 0.125 0.125 
E. coli TOP 10F’ + pK19-OXA-258a  16 2 8 2 0.5 ≤ 0.125 0.25 
E. coli TOP 10F’ + pK19-OXA-258b  8 2 8 2 0.25 ≤ 0.125 0.25 
A. ruhlandii 38  512 1024 256 256 8 64 32 
A. ruhlandii 319  512 1024 32 32 4 32 2 
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Table 2: Representative antibiotic MICs for A. ruhlandii 38 strain, E. coli TOP10F’ harboring 
pK19 plasmid, E. coli TOP10F’ harboring pK19 plasmid expressing AxyABM efflux pump, 
and E. coli TOP10F’ (reference strain). 
 
Isolates 
CHL (μg/ml) Inhibitio
n 
NAL (μg/ml) Inhibitio
n 
SXT (μg/ml) Inhibitio
n - 
PAβN 
+ 
PAβN 
- 
PAβN 
+ 
PAβN 
- 
PAβN 
+ 
PAβN 
TOP 10 ≤1 ≤1 - ≤0.5 ≤0.5 - 0.5 ≤0.25 - 
TOP 10 - pK19 ≤1 ≤1 - ≤0.5 ≤0.5 - ≤0.25 ≤0.25 - 
TOP 10 - pK19 - 
AxyABM 
16 ≤1 + 8 ≤0.5 + 1 ≤0.25 + 
A. ruhlandii 38 32 8 + 256 128 - 32 16 - 
 
Isolates 
CIP (μg/ml) Inhibi
tion 
NOR 
(μg/ml) 
Inhibi
tion 
CAZ (μg/ml) Inhibiti
on 
IPM 
(μg/ml) 
Inhibi
tion - 
PAβ
N 
+ 
PAβ
N 
- 
PAβ
N 
+ 
PAβ
N 
- 
PAβ
N 
+ 
PAβ
N 
- 
PA
βN 
+ 
PA
βN 
TOP 10 ≤0.1
25 
≤0.1
25 
- ≤0.0
3 
≤0.0
3 
- 0.12
5 
0.12
5 
- 0.2
5 
0.2
5 
- 
TOP 10 - pK19 ≤0.1
25 
≤0.1
25 
- ≤0.0
3 
≤0.0
3 
- 0.12
5 
0.12
5 
- 0.2
5 
0.2
5 
- 
TOP 10 - pK19 - 
AxyABM 
≤0.1
25 
≤0.1
25 
- 0.06 0.06 - 0.25 0.25 - 0.2
5 
0.2
5 
- 
A. ruhlandii 38 4 4 - 64 32 - 8 8 - 32 16 - 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
